Research Platform 2022: A novel test strategy to follow up patients at risk developing dementia

The goals of DetectDem are (1) to develop novel electrophysiological biomarkers using established state-of-the-art cryogenic magnetoencephalographic (MEG) data, (2) to translate those biomarkers to the more recently developed on-scalp MEG based on optically pumped magnetometers (OPMs) and to leverage the unique capacity to detect interictal epileptiform discharges as a potential precursor of cognitive deterioration and (3) to enable access and establish a patient community through personalised data vaults. Combined these three goals will enable long-term follow-up of patients in the earliest stages of possible AD. Such a long-term follow-up is crucial to retrospectively define the subtle electrophysiological fingerprint of AD in the earliest stages, correctly diagnose AD, and develop novel therapeutic strategies that must be introduced at the earliest stage of the disease.